Baker Bros. Advisors LP·13F Holdings
- Positions
- 21
- Top-10 weight
- 97%
- Largest
- INCY · 32%
- Quarter ending
- Jun 30, 2026
- Added
- 10
- Trimmed
- 2
- Sold out
- ARGX
- Last filed
- Aug 14, 2026
Portfolio
What does Baker Bros. Advisors LP own?
Baker Bros. Advisors LP reported 21 long equity positions worth $11.0B for the quarter ending Jun 30, 2026. The largest is INCY at 32% of reported value. The ten largest positions make up 97% of the portfolio. Against the prior quarter it added to 10 positions, trimmed 2 and sold out of 1. The latest 13F was filed Aug 14, 2026.
Largest positionsValue · weight
- INCYIncyte Corporation$3.5B32% of portfolio
- RVMDRevolution Medicines, Inc.$2.1B19% of portfolio
- MDGLMadrigal Pharmaceuticals Inc.$1.2B10% of portfolio
- KYMRKymera Therapeutics Inc.$992.7M9.0% of portfolio
- INSMInsmed Incorporated$937.8M8.5% of portfolio
- CELCCelcuity Inc.$828.2M7.5% of portfolio
- PRAXPraxis Precision Medicines Inc.$587.0M5.3% of portfolio
- ABCLAbCellera Biologics Inc.$259.1M2.3% of portfolio
- ROIVRoivant Sciences Ltd.$166.9M1.5% of portfolio
- ARWRArrowhead Pharmaceuticals Inc.$162.4M1.5% of portfolio
Sector tilt
Which sectors does Baker Bros. Advisors LP lean on?
Healthcare (71%) and Health technology (29%) are the two largest sectors by reported value.
By share of reported value, across 21 classified tickers.
Quarter changes
What did Baker Bros. Advisors LP buy and sell last quarter?
Largest additions last quarterEst. value
Largest reductions last quarterEst. value
Ownership stakes
Where is Baker Bros. Advisors LP a major shareholder?
By shares outstanding, Baker Bros. Advisors LP owns 15.1% of Incyte Corporation, 10.4% of Kymera Therapeutics Inc., 10.2% of AbCellera Biologics Inc. and 9.2% of Madrigal Pharmaceuticals Inc..
Reported value
How has Baker Bros. Advisors LP's 13F value moved?
Reported value went from $6.3B to $11.0B over 4 quarters. It moves with prices and with buying and selling, so it is not a fund return.
Latest 13F
What Baker Bros. Advisors LP changed in its latest 13F
| Company | Change | Shares vs prior | Est. value | Filed |
|---|---|---|---|---|
| Revolution Medicines, Inc. RVMD | +20% | $353.6M | Aug 14, 2026 | |
| Insmed Incorporated INSM | +19% | $146.6M | Aug 14, 2026 | |
| Relay Therapeutics, Inc. RLAY | +144% | $31.2M | Aug 14, 2026 | |
| Intellia Therapeutics, Inc. NTLA | -66% | $30.7M | Aug 14, 2026 | |
| AbCellera Biologics Inc. ABCL | +9.0% | $21.5M | Aug 14, 2026 | |
| Argenx SE American Depositary Shares ARGX | -100% | $18.4M | Aug 14, 2026 | |
| Cytokinetics Incorporated CYTK | New | $18.0M | Aug 14, 2026 | |
| Parabilis Medicines, Inc. PBLS | New | $13.7M | Aug 14, 2026 | |
| Arcus Biosciences, Inc. RCUS | +103% | $13.2M | Aug 14, 2026 | |
| Viridian Therapeutics, Inc. VRDN | +21% | $7.6M | Aug 14, 2026 | |
| Roivant Sciences Ltd. ROIV | -3.1% | $5.3M | Aug 14, 2026 | |
| Incyte Corporation INCY | +0.1% | $2.0M | Aug 14, 2026 | |
| Madrigal Pharmaceuticals Inc. MDGL | +0.1% | $768K | Aug 14, 2026 |
